[go: up one dir, main page]

WO2004046168A3 - Glycoproteines d'enveloppe recombinantes du vih-1 de sous-type d - Google Patents

Glycoproteines d'enveloppe recombinantes du vih-1 de sous-type d Download PDF

Info

Publication number
WO2004046168A3
WO2004046168A3 PCT/US2003/036653 US0336653W WO2004046168A3 WO 2004046168 A3 WO2004046168 A3 WO 2004046168A3 US 0336653 W US0336653 W US 0336653W WO 2004046168 A3 WO2004046168 A3 WO 2004046168A3
Authority
WO
WIPO (PCT)
Prior art keywords
subclass
hiv
glycoproteins
nucleic acid
recombinant hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/036653
Other languages
English (en)
Other versions
WO2004046168A2 (fr
Inventor
Thomas C Vancott
Mathew E Harris
Vaniambadi S Kalyanaraman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority to AU2003294297A priority Critical patent/AU2003294297A1/en
Publication of WO2004046168A2 publication Critical patent/WO2004046168A2/fr
Publication of WO2004046168A3 publication Critical patent/WO2004046168A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des molécules d'acides nucléiques recombinantes codant pour des glycoprotéines d'enveloppe gp140 recombinantes du VIH-1 de sous-type D, ainsi que les glycoprotéines codées par ces molécules. L'invention concerne également des vecteurs comprenant ces molécules d'acides nucléiques, ainsi que des compositions vaccinales comprenant lesdites molécules d'acides nucléiques ou lesdites glycoprotéines. L'invention concerne en outre un procédé permettant d'induire une réponse immunogène étendue vis-à-vis du VIH-1 pour neutraliser le virus VIH-1.
PCT/US2003/036653 2002-11-15 2003-11-17 Glycoproteines d'enveloppe recombinantes du vih-1 de sous-type d Ceased WO2004046168A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003294297A AU2003294297A1 (en) 2002-11-15 2003-11-17 Recombinant hiv-1 subclass d envelope glycoproteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42650002P 2002-11-15 2002-11-15
US60/426,500 2002-11-15

Publications (2)

Publication Number Publication Date
WO2004046168A2 WO2004046168A2 (fr) 2004-06-03
WO2004046168A3 true WO2004046168A3 (fr) 2005-04-14

Family

ID=32326362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036653 Ceased WO2004046168A2 (fr) 2002-11-15 2003-11-17 Glycoproteines d'enveloppe recombinantes du vih-1 de sous-type d

Country Status (2)

Country Link
AU (1) AU2003294297A1 (fr)
WO (1) WO2004046168A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2695484C (fr) 2007-08-20 2018-05-01 Glaxo Group Limited Procede de production de proteines therapeutiques fonde sur l'adaptation des codons

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028929A1 (fr) * 1993-06-07 1994-12-22 Genentech, Inc. Polypeptides d'enveloppe du vih
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
WO2000039302A2 (fr) * 1998-12-31 2000-07-06 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
WO2001060836A1 (fr) * 2000-02-18 2001-08-23 Taiho Pharmaceutical Co., Ltd. Procede de preparation de derives steroidiens

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
WO1994028929A1 (fr) * 1993-06-07 1994-12-22 Genentech, Inc. Polypeptides d'enveloppe du vih
US5864027A (en) * 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
WO2000039302A2 (fr) * 1998-12-31 2000-07-06 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
WO2001060836A1 (fr) * 2000-02-18 2001-08-23 Taiho Pharmaceutical Co., Ltd. Procede de preparation de derives steroidiens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIKANDOU B. ET AL.: "Genetic subtypes of HIV type 1 in Republic of Congo", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 16, no. 7, 1 May 2000 (2000-05-01), pages 613 - 619, XP002985424 *
ROBBINS K.E. ET AL.: "Genetic analysis of human immunodeficiency virus type 1 strains in Kenya: a comparison using phylogenetic analysis and a combinatorial melting assay", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 15, no. 4, 1 March 1999 (1999-03-01), pages 329 - 335, XP002985425 *

Also Published As

Publication number Publication date
AU2003294297A8 (en) 2004-06-15
WO2004046168A2 (fr) 2004-06-03
AU2003294297A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
WO2021155243A8 (fr) Compositions d'immunisation contre le virus respiratoire
IL182357A0 (en) Malaria prime/boost vaccines
WO2000067787A3 (fr) Compositions et procedes immunogenes anti-vih
WO2004112831A3 (fr) Virus influenza de recombinaison a titre eleve pour vaccins et therapie genique
WO2006068663A3 (fr) Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
WO2004000876A8 (fr) Adnc infectieux d'une souche vaccinale agreee du virus de la rougeole, et utilisation pour des compositions immunogenes
WO2004050856A3 (fr) Vaccins a adn polyvalents contre la glycoproteine du vih-1 primaire et procedes de vaccination
WO2004037189A3 (fr) Methodes de vaccination contre le paludisme
WO2003047617A3 (fr) Vaccin
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
EP2290091A3 (fr) Virus de la rougeole recombinants exprimant des epitopes d' antigenes de virus à ARN et utilisation des virus recombinants pour la preparation de vaccins
WO2003023040A3 (fr) Mutants du virus de la vaccine obtenus par inactivation de mva-e3l et leur utilisation
WO2004087062A3 (fr) Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
WO2001021807A8 (fr) Proteine enveloppe 2 (e2) du virus de l'hepatite c qui ne possede pas tout ou partie de la region 1 hypervariable (hvr1), acides nucleiques correspondants, virus chimeriques et utilisation de ces derniers
WO2005011571A3 (fr) Proteines du noyau du virus de l'hepatite utilisees comme plateformes de vaccins et leur utilisation
WO2008086386A3 (fr) Vaccins antipaludéens à base de vecteur adénoviral
FR2828405B1 (fr) Vaccin anti-coronavirus
WO2004046168A3 (fr) Glycoproteines d'enveloppe recombinantes du vih-1 de sous-type d
WO2004044167A3 (fr) Expression, purification et utilisation d'un polypeptide d'antigene lsa-1 de plasmodium falciparum
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
WO2003006654A3 (fr) Proteines de recombinaison de parapoxvirus ovis et compositions pharmaceutiques issues de celles-ci
PT1383796E (pt) Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
AU2003277909A1 (en) Recombinant mva strains as potential vaccines against p. falciparum malaria
WO2004031222A3 (fr) Vaccin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
WR Later publication of a revised version of an international search report
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP